NL186635B - 3-(4-fenyl-1-piperazinylalkyl) s-triazolo (4.3-a) azacycloalkanen met farmacologische werking, alsmede werkwijzen ter bereiding van deze verbindingen en farmaceutisch preparaat, bevattende deze verbindingen. - Google Patents

3-(4-fenyl-1-piperazinylalkyl) s-triazolo (4.3-a) azacycloalkanen met farmacologische werking, alsmede werkwijzen ter bereiding van deze verbindingen en farmaceutisch preparaat, bevattende deze verbindingen.

Info

Publication number
NL186635B
NL186635B NLAANVRAGE7902489,A NL7902489A NL186635B NL 186635 B NL186635 B NL 186635B NL 7902489 A NL7902489 A NL 7902489A NL 186635 B NL186635 B NL 186635B
Authority
NL
Netherlands
Prior art keywords
azacycloalcanes
piperazinylalkyl
triazolo
phenyl
preparing
Prior art date
Application number
NLAANVRAGE7902489,A
Other languages
English (en)
Other versions
NL7902489A (nl
NL186635C (nl
Original Assignee
Acraf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acraf filed Critical Acraf
Publication of NL7902489A publication Critical patent/NL7902489A/nl
Publication of NL186635B publication Critical patent/NL186635B/nl
Application granted granted Critical
Publication of NL186635C publication Critical patent/NL186635C/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
NLAANVRAGE7902489,A 1978-04-18 1979-03-30 3-(4-fenyl-1-piperazinylalkyl) s-triazolo (4.3-a) azacycloalkanen met farmacologische werking, alsmede werkwijzen ter bereiding van deze verbindingen en farmaceutisch preparaat, bevattende deze verbindingen. NL186635C (nl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT22421/78A IT1094076B (it) 1978-04-18 1978-04-18 Cicloalchiltriazoli

Publications (3)

Publication Number Publication Date
NL7902489A NL7902489A (nl) 1979-10-22
NL186635B true NL186635B (nl) 1990-08-16
NL186635C NL186635C (nl) 1991-01-16

Family

ID=11196066

Family Applications (1)

Application Number Title Priority Date Filing Date
NLAANVRAGE7902489,A NL186635C (nl) 1978-04-18 1979-03-30 3-(4-fenyl-1-piperazinylalkyl) s-triazolo (4.3-a) azacycloalkanen met farmacologische werking, alsmede werkwijzen ter bereiding van deze verbindingen en farmaceutisch preparaat, bevattende deze verbindingen.

Country Status (22)

Country Link
US (2) US4252721A (nl)
JP (1) JPS5817757B2 (nl)
AT (1) AT374477B (nl)
AU (1) AU520788B2 (nl)
BG (2) BG40654A3 (nl)
CA (1) CA1104567A (nl)
CH (1) CH639847A5 (nl)
DE (1) DE2915318A1 (nl)
DK (1) DK148480C (nl)
FI (1) FI66378C (nl)
FR (1) FR2423221A1 (nl)
GB (1) GB2020269B (nl)
HU (1) HU179917B (nl)
IE (1) IE47965B1 (nl)
IL (1) IL56926A (nl)
IT (1) IT1094076B (nl)
NL (1) NL186635C (nl)
PL (1) PL116103B1 (nl)
PT (1) PT69502A (nl)
SE (1) SE437663B (nl)
SU (1) SU852174A3 (nl)
YU (1) YU41338B (nl)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1248531A (en) * 1984-04-17 1989-01-10 Jeffrey C. Watkins 4-substituted piperazine-2-carboxylic acids
FR2580648B1 (fr) * 1985-04-17 1987-05-15 Adir Nouveaux derives du triazole, leur procede de preparation et les compositions pharmaceutiques les renfermant
US4879294A (en) * 1988-01-28 1989-11-07 Angelini Pharmaceuticals Ltd. Opthalmic composition
IT1224250B (it) * 1988-06-10 1990-09-26 Acraf Associzione del depiprazolo con la morfina
IT1250701B (it) * 1991-07-24 1995-04-21 Angelini Francesco Ist Ricerca Composizione farmaceutica solida per uso orale a base di dapiprazolo
US5288759A (en) * 1992-08-27 1994-02-22 Alcon Laboratories, Inc. Use of certain sulfamoyl-substituted phenethylamine derivatives to reverse drug-induced mydriasis
US6187774B1 (en) * 1996-03-04 2001-02-13 Yoshitomi Pharmaceutical Industries, Ltd. Fused heterocyclic compounds and pharmaceutical applications thereof
WO2000018391A1 (fr) 1998-09-30 2000-04-06 Takeda Chemical Industries, Ltd. Medicaments qui ameliorent le pouvoir de vidange de la vessie
IL141235A (en) * 2000-02-09 2012-04-30 Novartis Int Pharm Ltd Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
US6730691B1 (en) 2000-02-10 2004-05-04 Miles A. Galin Uses of alpha adrenergic blocking agents
US20020065286A1 (en) * 2000-08-21 2002-05-30 Davies Michael John Treatment of wounds
US20020091129A1 (en) * 2000-11-20 2002-07-11 Mitradev Boolell Treatment of premature ejaculation
KR20040014600A (ko) * 2001-07-02 2004-02-14 산텐 세이야꾸 가부시키가이샤 알파1 수용체 차단약을 유효 성분으로 하는 시신경 보호제
GB0130219D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Compounds for the treatment of sexual dysfunction
US20030229001A1 (en) * 2002-01-31 2003-12-11 Pfizer Inc. Treatment of male sexual dysfunction
AP2005003232A0 (en) 2002-08-19 2005-03-31 Pfizer Prod Inc Combination therapy for hyperproliferative diseases.
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
US7323462B2 (en) * 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
PA8597401A1 (es) * 2003-03-14 2005-05-24 Pfizer Derivados del acido 3-(1-[3-(1,3-benzotiazol-6-il) propilcarbamoil] cicloalquil) propanoico como inhibidores de nep
US20040220186A1 (en) * 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
GEP20084406B (en) * 2003-05-30 2008-06-25 Ranbaxy Lab Ltd Substituted pyrrole derivatives and their use as hmg-co inhibitors
US20050065158A1 (en) * 2003-07-16 2005-03-24 Pfizer Inc. Treatment of sexual dysfunction
US20050037063A1 (en) * 2003-07-21 2005-02-17 Bolton Anthony E. Combined therapies
US7291640B2 (en) * 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
US20050267096A1 (en) * 2004-05-26 2005-12-01 Pfizer Inc New indazole and indolone derivatives and their use pharmaceuticals
US20050288270A1 (en) * 2004-05-27 2005-12-29 Pfizer Inc New aminopyridine derivatives and their use as pharmaceuticals
ATE412648T1 (de) * 2005-03-21 2008-11-15 Pfizer Ltd Substituierte triazolderivate als oxytocinantagonisten
JP2008533193A (ja) * 2005-03-21 2008-08-21 ファイザー・リミテッド オキシトシン拮抗薬としての置換トリアゾール誘導体
EP1917257A1 (en) * 2005-08-10 2008-05-07 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
AU2006313430B2 (en) * 2005-11-08 2012-09-06 Ranbaxy Laboratories Limited Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7919506B2 (en) 2006-03-10 2011-04-05 Pfizer Inc. Dibenzyl amine compounds and derivatives
US8383660B2 (en) 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives
WO2008020314A2 (en) * 2006-03-14 2008-02-21 Ranbaxy Laboratories Limited Statin stabilizing dosage formulations
AU2007274724B2 (en) * 2006-07-14 2012-07-26 Ranbaxy Laboratories Limited Polymorphic forms of an HMG-CoA reductase inhibitor and uses thereof
US8404896B2 (en) 2006-12-01 2013-03-26 Bristol-Myers Squibb Company N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases
BR112015026513A2 (pt) 2013-04-17 2017-07-25 Pfizer derivados de n-piperidin-3-ilbenzamida para tratar as doenças cardiovasculares
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
MX2021004708A (es) 2018-10-26 2021-11-03 Ocuphire Pharma Inc Metodos y composiciones para tratamiento de presbicia, midriasis y otros trastornos oculares.
MX2021008533A (es) 2019-01-18 2021-08-19 Astrazeneca Ab Inhibidores de la pcsk9 y metodos de uso de los mismos.
CN115368310A (zh) 2021-05-18 2022-11-22 奥库菲尔医药公司 合成甲磺酸酚妥拉明的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2913454A (en) * 1956-11-23 1959-11-17 Schenley Ind Inc Certain cycloalkanotriazoles, process and intermediates
IT1066857B (it) * 1965-12-15 1985-03-12 Acraf Derivati della s ipiazolo 4.3 a piridina e processi per la loro preparazione
US3472853A (en) * 1967-05-29 1969-10-14 Sterling Drug Inc 1-((pyrido(2,1-c)-s-triazolyl)-lower-alkyl)-4-substituted- piperazines
JPS5070389A (nl) * 1973-10-30 1975-06-11

Also Published As

Publication number Publication date
IE790646L (en) 1979-10-18
GB2020269B (en) 1982-06-03
AT374477B (de) 1984-04-25
DK148480C (da) 1985-12-16
US4307095A (en) 1981-12-22
FI791217A (fi) 1979-10-19
DK148480B (da) 1985-07-15
PT69502A (en) 1979-05-01
YU41338B (en) 1987-02-28
BG40654A3 (en) 1987-01-15
AU520788B2 (en) 1982-02-25
DE2915318C2 (nl) 1990-12-13
DE2915318A1 (de) 1979-10-31
JPS5817757B2 (ja) 1983-04-09
US4252721A (en) 1981-02-24
YU86279A (en) 1983-12-31
DK156779A (da) 1979-10-19
CH639847A5 (it) 1983-12-15
BG61367B2 (bg) 1997-06-30
ATA292479A (de) 1983-09-15
NL7902489A (nl) 1979-10-22
PL116103B1 (en) 1981-05-30
SU852174A3 (ru) 1981-07-30
CA1104567A (en) 1981-07-07
SE437663B (sv) 1985-03-11
FI66378C (fi) 1984-10-10
IE47965B1 (en) 1984-08-08
FR2423221A1 (fr) 1979-11-16
AU4583279A (en) 1979-10-25
FR2423221B1 (nl) 1983-03-18
IL56926A0 (en) 1979-05-31
HU179917B (en) 1983-01-28
JPS54157576A (en) 1979-12-12
IT7822421A0 (it) 1978-04-18
GB2020269A (en) 1979-11-14
NL186635C (nl) 1991-01-16
IL56926A (en) 1983-09-30
SE7903327L (sv) 1979-10-19
IT1094076B (it) 1985-07-26
PL214969A1 (nl) 1980-03-10
FI66378B (fi) 1984-06-29

Similar Documents

Publication Publication Date Title
NL186635C (nl) 3-(4-fenyl-1-piperazinylalkyl) s-triazolo (4.3-a) azacycloalkanen met farmacologische werking, alsmede werkwijzen ter bereiding van deze verbindingen en farmaceutisch preparaat, bevattende deze verbindingen.
NL7902521A (nl) Werkwijze voor het bereiden van 2,2,6,6-tetramethyl- -4-piperidon.
NL189127C (nl) Werkwijze voor de bereiding van 1,1-diesters.
NO154165C (no) Fremgangsmaate ved fremstilling av 2,3,5-triklorpyridin.
NL7613872A (nl) Werkwijze ter bereiding van 4,4'-isopropylideen- -bis(2,6-dibroomfenol).
NL7902408A (nl) 3,7-digesubstitueerde-3-cefem-4-carbonzuurverbindingen en werkwijzen ter bereiding daarvan.
NO790583L (no) Stol for invalide.
IT7926662A0 (it) Composizione farmaceutica contenente 3,4-di-idro-3-osso-2-chinossaline.
NL7811562A (nl) Indolo/2,3-a/chinolizidinen, preparaten die ze bevat- ten, en werkwijzen voor de bereiding daarvan.
NL7603651A (nl) Werkwijze voor het bereiden van 3.4-dihydrospiro- -2h-1.3-benzooxazinen.
IT7926898A0 (it) Procedimento per preparare 1,2,3-tiadiazol-5-il-uree.
NL172541C (nl) Werkwijze voor de bereiding van 2,4-diamino-5-benzylpyrimidinen.
NL7902915A (nl) Werkwijze voor de bereiding van ketazine.
NL7705991A (nl) Werkwijze ter bereiding van 5,6-dihydroprosta- cycline-analoga.
NL7805142A (nl) Werkwijze ter bereiding van 1,5-dimethylbicyclo(3,2,1)- octanol-8.
NL7901164A (nl) Werkwijze voor het bereiden van beta-santalol, beta-santaleen, dihydro-beta-santalol en verwante verbindingen.
NL7608194A (nl) Werkwijze voor het bereiden van cyclohexaan- dionen-(1,3).
NL7806659A (nl) Rifamycineverbindingen.
NL7900396A (nl) Werkwijze voor de bereiding van aromatische aldehyden.
RO76177A (ro) Procedeu pentru prepararea octahidro-indolo-2,3-a/chinolizine-1,1-disubstituite
NL7708375A (nl) Werkwijze ter bereiding van farmaceutisch actieve verbindingen.
IT7925962A0 (it) Gruppo miscelatore.
IT7926059A0 (it) Pneumatico isostatico.
NL7709746A (nl) Werkwijze ter bereiding van benzimidazo-(1,2-a)-chi- nolinen.
NL7903062A (nl) Werkwijze ter bereiding van 1,4-bis-piperonylpiperazine en analoge verbindingen.

Legal Events

Date Code Title Description
BT A notification was added to the application dossier and made available to the public
BA A request for search or an international-type search has been filed
BB A search report has been drawn up
BC A request for examination has been filed
A85 Still pending on 85-01-01
V4 Discontinued because of reaching the maximum lifetime of a patent

Free format text: 19990330